NCT04860817 is a EARLY_PHASE1 clinical trial of Target CD7 CAR-T cells in T-cell Acute Lymphoblastic Leukemia, sponsored by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China.

What drugs are being tested in NCT04860817?

Interventions in NCT04860817: Target CD7 CAR-T cells.

What condition does NCT04860817 study?

NCT04860817 studies T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma.

Is NCT04860817 still recruiting?

NCT04860817 is currently withdrawn. Last updated 29 November 2022.

Last reviewed 2022-11-29 · How we verify

NCT04860817

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL

Withdrawn EARLY_PHASE1 Last updated 29 November 2022

What this trial tests

EARLY_PHASE1 trial testing Target CD7 CAR-T cells in T-cell Acute Lymphoblastic Leukemia. Withdrawn.

Timeline

1 December 2021

Primary endpoint
30 April 2023

1 November 2023

Quick facts

Lead sponsor	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase	EARLY_PHASE1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 December 2021
Primary completion	30 April 2023
Estimated completion	1 November 2023
Sites	1 location across China

Drugs / interventions tested

Target CD7 CAR-T cells — full drug profile →

Conditions studied

T-cell Acute Lymphoblastic Leukemia — all drugs for T-cell Acute Lymphoblastic Leukemia →
T-lymphoblastic Lymphoma — all drugs for T-lymphoblastic Lymphoma →

Sponsor

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Who can join

Adults 2 to 25, any sex, with T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

T cells are a type of immune cell. Like other cells of the body, T Cells can develop cancer. T cell cancers mainly include T cell leukaemia and T cell lymphoma, both of which have a relatively poor prognosis. Currently, patients with relapsed/refractory type (the name given to cancer that reappears or grows again after a period of no changes or signs of cancer) of this leukaemia or lymphoma have limited choices for treatment. CAR-T cells are immune cells that are engineered to target specific cell markers. For example, CAR-T cells targeting the marker CD19 have shown great effectiveness in the treatment of B cell tumors that carry this marker. Here investigators construct a new universal CAR-T design targeting CD7 which is found on the cells of relapsed/refractory type T cell leukaemia and lymphoma and hope to test its safety and efficiency in the treatment of relapsed/refractory type T cell leukaemia and lymphoma.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-T cell combination therapy: the next revolution in cancer treatment.
Al-Haideri M, Tondok SB, Safa SH, Maleki AH, et al · · 2022 · cited 106× · PMID 36419058 · DOI 10.1186/s12935-022-02778-6
Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies.
Sin CF, Man PM. · · 2021 · cited 31× · PMID 34912707 · DOI 10.3389/fonc.2021.750789
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.
Caracciolo D, Mancuso A, Polerà N, Froio C, et al · · 2023 · cited 18× · PMID 36624522 · DOI 10.1186/s40164-022-00368-w
Adoptive Cell Therapy for T-Cell Malignancies.
Fang KK, Lee JB, Zhang L. · · 2022 · cited 8× · PMID 36612092 · DOI 10.3390/cancers15010094
Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope.
Jing J, Ma Y, Xie Z, Wang B, et al · · 2024 · cited 4× · PMID 39192970 · DOI 10.3389/fimmu.2024.1410519

Verify or expand the search:

Other recruiting trials for T-cell Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT06561074 — A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Ad · Phase 2 · recruiting
NCT06514794 — A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lym · Phase 2 · recruiting
NCT06686108 — Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relap · Phase 2 · recruiting
NCT06420076 — Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using · Phase 1, PHASE2 · recruiting
NCT06316427 — Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies · Phase 1, PHASE2 · recruiting

Other 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China trials

Trials by the same sponsor.

NCT06675422 — JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) · Phase 1, PHASE2 · recruiting
NCT06514768 — JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) · EARLY_PHASE1 · recruiting
NCT06352281 — Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) · Phase 1, PHASE2 · recruiting
NCT06210243 — C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma · Phase 1 · terminated
NCT06110208 — Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML · EARLY_PHASE1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04860817 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Last refreshed: 29 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04860817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing